- Home
- BASE vs PRTA Comparison
BASE vs PRTA Comparison
Compare BASE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BASE
- PRTA
- Stock Information
- Founded
- BASE 2011
- PRTA 2012
- Country
- BASE United States
- PRTA Ireland
- Employees
- BASE N/A
- PRTA N/A
- Industry
- BASE EDP Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- BASE Technology
- PRTA Health Care
- Exchange
- BASE Nasdaq
- PRTA Nasdaq
- Market Cap
- BASE 834.0M
- PRTA 802.8M
- IPO Year
- BASE 2021
- PRTA N/A
- Fundamental
- Price
- BASE $19.25
- PRTA $14.01
- Analyst Decision
- BASE Buy
- PRTA Buy
- Analyst Count
- BASE 13
- PRTA 7
- Target Price
- BASE $23.31
- PRTA $57.67
- AVG Volume (30 Days)
- BASE 261.2K
- PRTA 476.3K
- Earning Date
- BASE 12-03-2024
- PRTA 11-12-2024
- Dividend Yield
- BASE N/A
- PRTA N/A
- EPS Growth
- BASE N/A
- PRTA N/A
- EPS
- BASE N/A
- PRTA N/A
- Revenue
- BASE $198,818,000.00
- PRTA $133,350,000.00
- Revenue This Year
- BASE $17.65
- PRTA $60.63
- Revenue Next Year
- BASE $15.17
- PRTA N/A
- P/E Ratio
- BASE N/A
- PRTA N/A
- Revenue Growth
- BASE 21.00
- PRTA N/A
- 52 Week Low
- BASE $13.53
- PRTA $14.00
- 52 Week High
- BASE $32.00
- PRTA $41.55
- Technical
- Relative Strength Index (RSI)
- BASE 69.59
- PRTA 31.91
- Support Level
- BASE $15.65
- PRTA $17.27
- Resistance Level
- BASE $20.11
- PRTA $18.60
- Average True Range (ATR)
- BASE 0.60
- PRTA 1.11
- MACD
- BASE 0.26
- PRTA -0.15
- Stochastic Oscillator
- BASE 80.74
- PRTA 0.20
About BASE Couchbase Inc.
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).